NewAmsterdam Pharma Company NAMS Change In Fair Value Of Derivative Earnout And Warrants
Change In Fair Value Of Derivative Earnout And Warrants at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept nams:ChangeInFairValueOfDerivativeEarnoutAndWarrants.
The official record: NewAmsterdam Pharma Company’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about NewAmsterdam Pharma Company's change in fair value of derivative earnout and warrants.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is NewAmsterdam Pharma Company's change in fair value of derivative earnout and warrants?
- NewAmsterdam Pharma Company (NAMS) reported change in fair value of derivative earnout and warrants of -$5.94M in Q1 2026.
- How has NewAmsterdam Pharma Company's change in fair value of derivative earnout and warrants changed year-over-year?
- NewAmsterdam Pharma Company's change in fair value of derivative earnout and warrants increased by 66.5% year-over-year, from -$17.75M to -$5.94M.
- What does change in fair value of derivative earnout and warrants mean?
- This reflects the non-cash gain or loss resulting from the periodic revaluation of derivative instruments, such as earnout obligations or warrants. Because these fluctuations are driven by market conditions rather than core operational performance, they are adjusted to arrive at cash flow from operations. It highlights the impact of financial instrument volatility on the company's reported earnings.